Psychiatric Adverse Effects of Montelukast—A Nationwide Cohort Study
The Journal of Allergy and Clinical Immunology: In Practice · 2023
DOI: 10.1016/j.jaip.2023.03.010 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023. Verfasst von Alexander Jordan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Respiratory Medicine, Copenhagen University Hospital-Gentofte, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Asthma, Quinolines, Drug-Related Side Effects and Adverse Reactions, Anti-Asthmatic Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Novo Nordisk Fonden.
Abstract (Originalsprache)
BACKGROUND: Recent observational studies suggest that the leukotriene receptor antagonist montelukast may have neuropsychiatric adverse effects; however, results are conflicting. OBJECTIVE: To assess whether montelukast exposure in adults with asthma is associated with onset of neuropsychiatric adverse events using data from the Danish nationwide health registers. METHODS: Individuals 18 years old or older with either 1 or more prescription redemption of inhaled corticosteroids or with at least 1 hospital contact with asthma as the main diagnosis between January 1, 2011, and December 31, 2018, were included. Montelukast exposure was assessed as a time-dependent variable. The 2 outcomes of interest were use of neuropsychiatric medicine including antidepressants, antipsychotics, anxiolytics, lithium, and medication used for attention-deficit/hyperactivity disorder (outcome 1), and hospital contacts with a neuropsychiatric diagnosis (outcome 2), within 90 days of exposure to montelukast. RESULTS: Initiation of montelukast was significantly associated with outcome 1: use of neuropsychiatric medicine (hazard ratio [95% confidence interval]) 1.14 [1.08-1.20]; P < .0001). In the assessment of outcome 2: hospital contacts with a neuropsychiatric diagnosis, a significant risk associated with montelukast initiation was found only in the youngest age groups (hazard ratio [95% confidence interval] 1.28 [1.12-1.47], P < .001 and 1.16 [1.02-1.31]; P < .05, for age group 18-29 y and 30-44 y, respectively). Age-stratified analyses showed that the risk of both outcomes increased with decreasing age, with the highest risk seen in patients aged 18 to 29 years. CONCLUSIONS: Among younger individuals, montelukast use was significantly associated with an increased risk of neuropsychiatric events such as use of neuropsychiatric medicine and hospital treatment. Clinicians should increase awareness of such adverse effects when prescribing montelukast.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Respiratory Medicine, Copenhagen University Hospital-Gentofte, Copenhagen, Denmark.
- Section of Respiratory Medicine, Copenhagen University Hospital-Gentofte, Copenhagen, Denmark; Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Copenhagen, Denmark. Electronic address: Louise…
- Section of Respiratory Medicine, Copenhagen University Hospital-Gentofte, Copenhagen, Denmark; Department of Respiratory Medicine, Zealand University Hospital-Roskilde, Copenhagen, Denmark.
- Section of Respiratory Medicine, Copenhagen University Hospital-Gentofte, Copenhagen, Denmark; Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Copenhagen, Denmark.
- Copenhagen Prospective Studies on Asthma in Childhood, Copenhagen University Hospital-Gentofte, Copenhagen, Denmark.
- Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Copenhagen, Denmark.
Förderung
- Novo Nordisk Fonden
Zitieren
APA
Jordan, A., Toennesen, L. L., Eklöf, J., Sivapalan, P., Meteran, H., Bønnelykke, K., Ulrik, C. S., & Stæhr Jensen, J. U. (2023). Psychiatric Adverse Effects of Montelukast—A Nationwide Cohort Study. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2023.03.010
Vancouver
Jordan A, Toennesen LL, Eklöf J, Sivapalan P, Meteran H, Bønnelykke K, et al. Psychiatric Adverse Effects of Montelukast—A Nationwide Cohort Study. The Journal of Allergy and Clinical Immunology: In Practice. 2023. doi:10.1016/j.jaip.2023.03.010
BibTeX
@article{Jordan2023,
author = {Jordan, Alexander and Toennesen, Louise Lindhardt and Eklöf, Josefin and Sivapalan, Pradeesh and Meteran, Howraman and Bønnelykke, Klaus and Ulrik, Charlotte Suppli and Stæhr Jensen, Jens-Ulrik},
title = {Psychiatric Adverse Effects of Montelukast—A Nationwide Cohort Study},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2023},
doi = {10.1016/j.jaip.2023.03.010}
}
EUVIMED